Niagen Bioscience, Inc. — Director's Dealing 2022

Apr 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2022-04-15

Reporting Person: Cohen Ann (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-15	Stock Option (right to buy)	$2.14	A	40000	Acquired	2032-04-14	Common Stock (40000.0)	Direct

Footnotes

F1: The option vests in three substantially equal annual installments beginning on April 15, 2023.